TY - JOUR
T1 - Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus
AU - Bellini, Carlo
AU - Campone, Francesco
AU - Serra, Giovanni
PY - 2006/6/20
Y1 - 2006/6/20
N2 - Patent ductus arteriosus is one of the most common congenital abnormalities found in premature infants. Ibuprofen, a nonsteroidal drug that is commonly used as an antipyretic, analgesic and anti-inflammatory agent, is also used to induce closure of symptomatic patent ductus arteriosus in preterm infants. Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension. Only 3 cases of pulmonary hypertension following early administration of an ibuprofen solution buffered with tromethamine have previously been reported. However, this severe side effect has never been observed in multicentre, randomized, double-blind controlled trials, nor in recent reviews or meta-analyses of L-lysine ibuprofen use.
AB - Patent ductus arteriosus is one of the most common congenital abnormalities found in premature infants. Ibuprofen, a nonsteroidal drug that is commonly used as an antipyretic, analgesic and anti-inflammatory agent, is also used to induce closure of symptomatic patent ductus arteriosus in preterm infants. Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension. Only 3 cases of pulmonary hypertension following early administration of an ibuprofen solution buffered with tromethamine have previously been reported. However, this severe side effect has never been observed in multicentre, randomized, double-blind controlled trials, nor in recent reviews or meta-analyses of L-lysine ibuprofen use.
UR - http://www.scopus.com/inward/record.url?scp=33745672959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745672959&partnerID=8YFLogxK
U2 - 10.1503/cmaj.051446
DO - 10.1503/cmaj.051446
M3 - Article
C2 - 16785458
AN - SCOPUS:33745672959
VL - 174
SP - 1843
EP - 1844
JO - Canadian Medical Association Journal
JF - Canadian Medical Association Journal
SN - 0008-4409
IS - 13
ER -